Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | WNT3 | P56703 | 1/20 | 0.39 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476303 | 1.00 | KMT2A (0.41) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL540990 | 1.00 | KMT2A (0.41) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL1604617 | 0.91 | MMP2 (0.38) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL1604618 | 0.91 | MMP2 (0.38) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL18018362 | 0.91 | MMP2 (0.38) | KMT2ACHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL713924 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL1372911 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL12105456 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL30289778 | 0.91 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL6743320 | 0.88 | CHRM2 (0.38) | CHRM2CHRM1CHRM3WNT3SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024054625-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | MEDIC LIFE SCIENCES, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2009023473-A2 | ANTIMICROBIAL PARENTERAL FORMULATION | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-02-19 | — | — | WO | disclosed |
| US-20090042932-A1 | ANTIMICROBIAL PARENTERAL FORMULATION | TAIGEN BIOTECHNOLOGY COMPANY LTD. (TW) | 2009-02-12 | — | — | US | disclosed |
| US-7456279-B2 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-7041696-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1513844-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003106460-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042932-A1 | ANTIMICROBIAL PARENTERAL FORMULATION | SLC10A2, ABCB11, SLC47A1 | KMT2A 4823/4885CHRM2 4147/4885CHRM1 4067/4885 |
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CCNI, CDK17 | KMT2A 826/4885CHRM2 4866/4885CHRM1 4728/4885 |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KMT2A 2479/4885CHRM2 1129/4885CHRM1 1838/4885 |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | DPP4, DPP7, DPP3 | KMT2A 1506/4885CHRM2 2158/4885CHRM1 1676/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | KMT2A 3154/4885CHRM2 4816/4885CHRM1 4813/4885 |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | KMT2A 1277/4885CHRM2 4844/4885CHRM1 4761/4885 |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | KMT2A 2154/4885CHRM2 4793/4885CHRM1 4605/4885 |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | KMT2A 966/4885CHRM2 4374/4885CHRM1 3852/4885 |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | KMT2A 1467/4885CHRM2 422/4885CHRM1 387/4885 |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1R1, IL1B, IL1RN | KMT2A 3683/4885CHRM2 1812/4885CHRM1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.